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Prostate cancer is the most commonly diagnosed cancer in 
men and one of the leading causes of cancer death in the 
United States.1 Although prostate cancer is frequently cur-
able in its early stage by surgical or radiation ablation, many 
patients present with locally advanced or metastatic disease 
for which there are currently no curative treatment 
options.2,3 Docetaxel-based chemotherapy has recently 
been introduced for the treatment of metastatic prostate 
cancer, following demonstration of its survival benefit in 
advanced hormone-resistant prostate cancer patients.4,5 
However, additional effective therapies with more favor-
able adverse effect profiles that can cure localized tumors 
and prevent their metastasis are urgently needed.
Tumor suppressors regulate diverse pathways to block 
tumor growth. We have shown previously that intratumor 
injection of c-myc promoter binding protein (MBP-1) inhib-
its prostate tumor growth in xenograft nude mice and induces 
cell death in a number of cancer cells without affecting 
the normal cell growth.6-8 MBP-1 was originally described 
to bind to and repress c-myc promoter function,9 but 
subsequent investigation has demonstrated that the tumor 
suppressor function of MBP-1 is not solely dependent on 
c-myc repression.7,10,11 However, the mechanism of MBP-1–
mediated inhibition of prostate cancer cell growth is poorly 
understood. We hypothesized that MBP-1 could exert its 
antitumor action by differentially regulating expression of 
microRNA (miRNA). miRNA are transcribed genes pro-
cessed to single-stranded regulatory RNA of ~22 nucleo-
tides.12 Mature miRNA repress protein expression primarily 
through base pairing of a seed region with the 3′ untranslated 
region (UTR) of the target mRNA leading to inhibition of 
translation and/or mRNA degradation. An individual 
miRNA is capable of regulating dozens of distinct mRNAs, 
and together the >650 human miRNA are believed to modu-
late more than one-third of the mRNA species encoded in 
the genome.13 Some miRNAs play a role in growth control 
or apoptosis, providing a mechanistic underpinning for the 
relation between miRNA and cancer.14-16 Moreover, miRNA 
involved in specific networks, such as the apoptotic, prolif-
eration, or receptor-driven pathways, could likely influence 
the response to targeted therapies or to chemotherapy. 
1Department of Pathology, Saint Louis University, St. Louis, MO, USA
2Mayo Clinic Center for Cell Signaling in Gastroenterology, Rochester, 
MN, USA
3Department of Internal Medicine, Saint Louis University, St. Louis, MO, 
USA
4Cancer Center, Saint Louis University, St. Louis, MO, USA
Corresponding Author:
Ratna B. Ray, Department of Pathology, Saint Louis University, 1100 South 
Grand Boulevard, St. Louis, MO 63104 
Email:  rayrb@slu.edu
MBP-1 Upregulates miR-29b,  
Which Represses Mcl-1, Collagens,  
and Matrix Metalloproteinase-2 in  
Prostate Cancer Cells
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Abstract
c-myc promoter binding protein (MBP-1) is a multifunctional protein known to regulate expression of targets involved in the malignant phenotype. We 
have previously demonstrated that exogenous expression of MBP-1 inhibits prostate tumor growth, although the mechanism of growth inhibition is not 
well understood. We hypothesized that MBP-1 may modulate microRNA (miRNA) expression for regulation of prostate cancer cell growth. In this study, 
we demonstrated that exogenous MBP-1 upregulates miR-29b by 5- to 9-fold in prostate cancer cells as measured by real-time quantitative reverse 
transcription polymerase chain reaction. Subsequent studies indicated that exogenous expression of miR-29b inhibited Mcl-1, COL1A1, and COL4A1. 
Furthermore, a novel target with potential implications for invasion and metastasis, matrix metallopeptidase-2 (MMP-2), was identified and confirmed to 
be a miR-29b target in prostate cancer cells. Together, these results demonstrated that exogenous expression of miR-29b regulates prostate cancer cell 
growth by modulating antiapoptotic and prometastatic matrix molecules, implicating the therapeutic potential of miR-29b for prostate cancer inhibition.
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A differential expression of a subset of miRNA between 
normal tissue and cancer and between cancers has been 
noted.14,15 We identified a number of altered miRNA expres-
sion upon enforced MBP-1 expression and chose to examine 
the function of miR-29b induction in prostate cancer cells, 
which could be a downstream mediator of tumor suppres-
sion by MBP-1, because miR-29b plays a role in regulating 
antiapoptotic and prometastatic proteins.
In this report, we have observed that MBP-1 upregulates 
miR-29b in prostate cancer cells, which in turn inhibits 
Mcl-1, matrix metallopeptidase-2 (MMP-2), and collagen 
expression. These results also add to the growing list of 
miRNAs that regulate tumor growth and provide a potential 
mechanism for how MBP-1 suppresses tumor growth by 
altering the expression of miRNA.
Results
MBP-1 upregulates miR-29b. MBP-1 has already been 
shown to regulate the expression of multiple genes involved 
in cell growth metastasis.7,10 Preliminary microarray analy-
sis comparing the expression profile of miRNA between 
prostate cancer PC3 cells transduced with AdMBP-1 or 
control virus (dl312) showed an alteration of the expression 
of 7 miRNA (R. Ray and R. Steele, manuscript in prepara-
tion). We chose to focus our investigation on miR-29b 
because it was reported to be involved with the regulation 
of cell proliferation, apoptosis, and migration. Quantitative 
reverse transcription polymerase chain reaction (RT-PCR) 
demonstrated miR-29b was significantly upregulated (6- to 
8-fold) by enforced MBP-1 expression in PC3 and DU145 
prostate cancer cell lines (Fig. 1).
miR-29b inhibits Mcl-1 in PC3 cells. Mcl-1 is an antiapop-
totic Bcl-2 family member protein that is highly regulated 
in normal cells, and when dysregulated, it contributes to 
cancer. Enhanced Mcl-1 expression has been observed in 
multiple human cancers, often in association with poor 
prognosis, disease recurrence, or drug resistance.17 miR-
29b was shown to directly downregulate translation of the 
Mcl-1 protein in cholangiocarcinoma cell lines.17 We tested 
whether ectopic expression of miR-29b could alter Mcl-1 
protein expression in prostate cancer cells. A significant 
reduction in Mcl-1 protein was observed in the PC3 cell 
line upon introduction of miR-29b as compared with con-
trol miRNA exposed PC3 cells (Fig. 2A). However, we 
could not detect Mcl-1 expression in DU145 cells. Con-
versely, anti–miR-29b enhanced Mcl-1 expression in PC3 
cells as compared with control anti-miR–treated cells (Fig. 
2B). Densitometric scanning of protein bands suggested an 
~60% reduction in Mcl-1 protein in the PC3 cells express-
ing miR-29b, whereas anti–miR-29b–expressing cells dis-
play enhanced Mcl-1 expression (~75%). The blots were 
probed with actin for similar protein load. Densitometric 
scanning results are presented after normalization of pro-
tein load. Furthermore, the signals from Figure 2A cannot 
be compared with Figure 2B because they were from 2 dif-
ferent gels and exposed for different length of time.
To further determine if miR-29b inhibits Mcl-1 3′UTR, 
we performed the luciferase assay by cotransfecting Mcl-1 
(wt) or Mcl-1 (mt) with miR-29b precursor. In parallel, we 
used the GAPDH 3′UTR, which is not a miR-29b target, 
downstream of luciferase as a control. Our results showed 
that expression miR-29b inhibits luciferase activity (70%) 
of Mcl-1 (wt) but not the mutant form (Fig. 2C). Together, 
these results suggest that miR-29b may have a cell growth 
inhibitory effect by altering antiapoptotic protein expres-
sion in prostate cancer cells.
Collagens are directly targeted by miR-29b in prostate can-
cer cells. Recently, the miR-29 family was shown to inhibit 
collagen mRNA expression in nasopharyngeal carcinomas 
and osteoblast differentiation.18,19 To determine if miR-29b 
regulated collagen expression in prostate cancer cell lines, 
we used a firefly luciferase reporter containing the relevant 
miR-29b binding sites (COL1A1, COL3A1, and COL4A1) 
in the luciferase 3′UTR. In parallel, we used the GAPDH 
3′UTR, which is not a miR-29b target, downstream of 
luciferase as a control. Prostate cancer cells were trans-
fected with these constructs with or without miR-29b mimic 
transfection. The 3′UTRs of all of these 3 candidate target 
genes (collagen 1A1, 3A1, and 4A1) elicited significantly 
decreased luciferase activities in miR-29b mimic trans-
fected cells (Fig. 3). As expected, we did not observe 
an inhibition of GAPDH 3′UTR. Mutant 3′UTRs of all of 
these 3 candidate target genes (nucleotide substitutions 
miR-29b Expression (fold difference)
PC3 DU145
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Figure 1. c-myc promoter binding protein (MBP-1) upregulates miR-
29b in prostate cancer cells. PC3 and DU145 cells were transduced 
with control dl312 or AdMBP-1 for 48 hours. Total RNA was isolated, 
and expression of miR-29b was measured using quantitative reverse 
transcription polymerase chain reaction with a hydrolysis probe and 
standardized to small nuclear RNA U6, which was used as the endogenous 
control. The results are presented from 3 independent experiments, mean 
± standard error. P < 0.001 by 1-way analysis of variance.
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disrupting the miR-29b binding sites) 
was also used. miR-29b did not alter 
the luciferase activity of these 
mutants. Similarly, control miRNA 
did not alter the luciferase activity of 
COL1A1, COL3A1, and COL4A1.
miR-29b inhibits collagen mRNA 
expression in prostate cancer cells. To 
test whether miR-29b indeed regu-
lates the levels of the candidate target 
mRNAs, we transfected miR-29b 
mimic into PC3 cells. Cells were also 
transfected in parallel with a control 
mimic miRNA. In PC3 cells, 2 poten-
tial miR-29b target mRNAs were 
reduced significantly by miR-29b 
mimic transfection: COL1A1 and 
COL4A1 (Fig. 4). Collagen 3A1 
mRNA expression was undetectable 
in PC3 cells, so its inhibition could 
not be determined. The reason for 
lack of collagen 3A1 mRNA in PC3 
cells is not clear at present. Specifi-
cally, COL1A1 mRNA levels were 
35% of control levels, whereas 
COL4A1 mRNA levels were reduced 
to 25%. Similar results were obtained 
when PC3 cells were transduced with 
AdMBP-1 (data not shown).
miR-29b inhibits MMP-2 expression. 
MMP-2, a zymogen requiring proteo-
lytic activation for catalytic activity, 
has been implicated broadly in inva-
sion and metastasis of many cancer 
model systems, including prostate 
cancer.20-22 MMP-2 has been shown 
to be activated by collagen type 1,23 and 
once activated, it degrades type 4 col-
lagen in the basement membrane. Using 
the Targetscan computer prediction 
method, a putative miR-29b target 
site in MMP-2 3′UTR was noted 
(Fig. 5A). To examine whether miR-
29b inhibits MMP-2 expression, we 
performed Western blot analysis in 
control or miR-29b mimic trans-
fected PC3 cells. Our results demon-
strated a significant downregulation 
of pro-MMP-2 in miR-29b–trans-









































































































Figure 2. miR-29b modulates Mcl-1 expression. (A) Exogenous expression of miR-29b inhibits Mcl-1 
expression in PC3 cells. Cells transfected with control miRNA, or miR-29b, were analyzed for Mcl-1 
protein expression by Western blot using specific antibody. The blot was reprobed with actin antibody 
to compare protein load. (B) Anti–miR-29b upregulates Mcl-1 expression in PC3 cells. PC3 cells were 
transfected with control or anti–miR-29b. Cell lysates were analyzed by Western blot for expression 
of specific proteins as described in A. Densitometric scanning of protein bands suggested a ~60% 
reduction in Mcl-1 protein in PC3 cells expressing miR-29b, whereas anti–miR-29b–expressing cells 
display enhanced Mcl-1 expression (~75%). The blots were probed with actin for similar protein load. 
Densitometric scanning data are presented after normalization of protein load. (C) DU145 cells were 
cotransfected with Mcl-1–derived 3′UTR insert (Mcl-1 wt) or luciferase with the mutated insert 
at 3′UTR (Mcl-1 mt) and miR-29b expression plasmid DNAs. GAPDH 3′UTR luciferase construct 
was used as an additional control. Luciferase activity was measured after 48 hours of transfection. 
Luciferase activity from GADPH 3′UTR-transfected cells was arbitrarily set as 100%. The results are 
presented as mean ± standard error from 3 independent experiments. P < 0.001 by 1-way analysis of 
variance.
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the effect of miR-29b on MMP-2 mRNA level, total RNA 
was isolated from PC3 cells transiently or stably transfected 
with the mimic miR-29b or miR-29b expression construct. 
Control miR was used in parallel. MMP-2 message was 
quantitated by real-time RT-PCR. We did not observe a sig-
nificant difference in mRNA level between control and 
cells expressing miR-29b. Therefore, it appears that miR-
29b does not affect MMP-2 mRNA expression. On the 
other hand, MMP-2 promoter activity was downregulated 
by MBP-1 in a dose-dependent manner.10 Thus, these can-
cer-relevant targets could be repressed directly by MBP-1, 
miR-29b, or both. Together, this result suggested that miR-
29b mediated pro-MMP-2 inhibition may serve as an addi-
tional layer of repression of MMP-2 function.
Discussion
miRNAs play a role in growth control or apoptosis, and a 
differential expression of a subset of miRNA between normal 
tissue and cancer and between cancers has been noted.14-16 
We hypothesized that MBP-1, a transcriptional co-repressor 
that regulates the expression of multiple genes, might directly 
or indirectly regulate expression of miRNA that modulate the 
cancer phenotype. Indeed, we have demonstrated that MBP-1 
stimulates miR-29b expression in 2 prostate cancer cell lines. 
miR-29b is of interest because it is involved with regulation 
of apoptosis and prometastatic molecules with which MBP-1 
was already implicated. Preliminary study also suggested 
that the basal expression level of miR-29b is decreased in 3 
of 4 prostate cancer specimens examined as compared with 
nontumorigenic benign prostatic hyperplasia specimens (R. 
Ray and G. Deng, unpublished observation). The salient 
findings of the current study address the molecular mecha-
nisms whereby the MBP-1/miR-29b axis could regulate 
prostate cancer malignant behaviors. Specifically, in prostate 
cancer cell lines, the MBP-1–induced miR-29b regulates 1) 
Mcl-1, 2) collagens, and 3) MMP-2. Each of these targets 
will be addressed below.
The antiapoptotic protein Mcl-1 is frequently overex-
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Figure 3. miR-29b inhibits expression of luciferase with 3′UTRs derived 
from its target genes. 3′UTR of target genes containing miR-29b–binding 
sites were cotransfected with miR-29b mimic into prostate cancer cells. 
Luciferase activity was measured after 48 hours of transfection. Luciferase 
activity from GADPH 3′UTR transfected cells was arbitrarily set as 100%. 
The results are presented as mean ± standard error from 3 independent 
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Figure 4. miR-29b downregulates collagen mRNA expression. PC3 cells 
transfected with control miRNA and miR-29b precursor for 48 hours. Total 
RNA was isolated and COL1A1 and COL4A1 mRNA was quantified using 
reverse transcription quantitative polymerase chain reaction. GAPDH was 
used as an internal control and normalized for relative mRNA expression. 
mRNA from control miRNA transfected cells was arbitrarily set as 100%. 
The result presented was the mean from 3 independent experiments. P < 
0.001 by 1-way analysis of variance.
Figure 5. miR-29b targets matrix metallopeptidase-2 (MMP-2) and 
represses pro–MMP-2 protein expression. (A) Computational analysis of 
the MMP-2 3′UTR revealed a single putative miR-29b binding site with base 
complementarity at positions 2 to 8 relative to the miR-29b 5′ terminus. 
This putative binding site retains perfect conservation in the MMP-2 3′UTR 
of human, primate, mouse, rat, and dog genomes. The miR-29b target region 
of MMP-2 (NM_004530; isoform a) is indicated, with numbering from 
the 1st nucleotide of the MMP-2 cDNA. (B) PC3 cells transfected with 
control miRNA or miR-29b were analyzed for MMP-2 protein expression 
by Western blot. The blot was reprobed with actin antibody to compare 
protein load. Densitometric analysis indicated 80% inhibition of pro–MMP-2 
protein expression. Blot is representative of 3 independent experiments.
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genomic amplification,24 transcriptional induction, post-
transcriptional regulation,25 and loss of microRNA func-
tion.26 Mcl-1 protein is found at elevated levels in prostate 
cancer,27 with more Mcl-1–positive cells in Gleason grade 8 
to 10 tumors than lower grade tumors.28 Furthermore, 
Mcl-1 induction in prostate cancer cells by the inflamma-
tory cytokine IL-6 provides resistance to apoptosis.29 Thus, 
Mcl-1 in prostate cancer, as in other malignancies, is a cen-
tral mediator of the resistance to apoptosis. In this study, we 
have observed that MBP-1–induced miR-29b inhibits 
Mcl-1 protein levels, consistent with previous work.26
Increased extracellular levels of collagens have been 
shown to induce increased invasiveness in culture and 
increased metastasis in animal models. Similarly, increased 
levels of collagens have been associated with an increased 
likelihood of clinical metastasis of multiple human solid 
tumors.30 Using laser capture isolated tumor cells, Sengupta 
and others18 have shown that nasopharyngeal carcinoma 
cells upregulate collagen mRNAs. Collagen type I contrib-
utes to invasiveness and metastasis in pancreatic cancer.31,32 
Furthermore, in prostate cancer, the alpha-1 chain of type 
IV collagen (COL4A1) is produced by malignant cells and 
increased with increasing tumor grade,33 suggesting a role 
in tumor pathology. Thus, our finding that miR-29b regu-
lates COL1A1, COL3A1, and COL4A1 is consistent with 
enhanced collagen production upon miR-29b repression, 
potentially facilitating metastatic activity. Conversely, 
MBP-1 induction of miR-29b and inhibition of collagen 
production may present a useful therapeutic goal.
MMP-2 is a key enzyme in the process of extracellular 
matrix remodeling involved in tumor invasion and metastasis. 
In hepatocellular carcinomas, increased collagen I mRNA 
levels were strongly associated with those of MMP-2.34 
Collagen I induces MMP-2 activation in breast cancer cells 
and hepatocellular carcinoma.24,34 We demonstrated here 
that MMP-2 is a predicted target of miR-29b, and we 
recently showed that MBP-1 expression reduced active 
MMP-2 in breast cancer cells.10 Here, we have observed 
that miR-29b inhibits pro–MMP-2 protein expression in 
PC3 cells. Although MMP-2 activation is directly inhibited 
by MBP-1, inhibition by miR-29b could be another mecha-
nism, and a working model is proposed (Fig. 6). This pos-
sibility is supported by the observation that expression in 
MBP-1 in PC3 cells upregulated miR-29b and enforced 
miR-29b expression downregulated MMP-2. MMP-2 is a 
protein with significance in prostate cancer, as MMP-2–
mediated degradation of type IV collagen in the basement 
membrane may promote metastatic invasion. Thus, 
although both the alpha-1 chain of collagen IV and the type 
IV metalloproteinase MMP-2 are targeted by miR-29b, the 
end result of low miR-29b may be increased turnover of 
basement membranes consistent with active remodeling of 
the extracellular matrix.
The mechanism by which MBP-1 induces miR-29b was 
not investigated. As miR-29b is repressed by c-myc expres-
sion,35 it is plausible that MBP-1 decreases c-myc in PC3 
and DU145 cells, allowing the de-repression of mir-29b. 
Further experiments will be necessary to confirm this 
hypothesis. In conclusion, our results demonstrated a mech-
anistic insight into miRNA function in prostate cancer cells. 
We have shown that miR-29b targets antiapoptotic and pro-
metastatic molecules in prostate cancer cells for regulation 
of growth. These results suggest that further preclinical tri-
als are needed to establish whether miR-29b could also be 
useful alone or in combination with conventional chemo-
therapeutics or conventional targeted agents for the treat-
ment of prostate cancer.
Materials and Methods
Cell lines and cell culture. PC3 and DU145 cell lines were 
purchased from American Type Culture Collection and 
maintained in DMEM containing 10% fetal bovine serum, 




Western blot analysis. PC3 and DU145 cells were trans-
duced with a replication deficient adenoviral vector express-
ing MBP-1 (AdMBP-1; 7) or dl312 control virus, and cell 
lysates were prepared 48 hours postinfection in 2x SDS-
sample buffer. Similarly, cells were transfected with miR-
29b mimic or control miRNA (random sequence Pre-miR 
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Figure 6. A schematic diagram showing the hypothetical cross-regulation 
of c-myc promoter binding protein (MBP-1), miR-29b, Mcl-1, collagen, and 
matrix metallopeptidase-2 (MMP-2) in inhibition of prostate cancer cell 
growth and invasion. The transcriptional co-repressor MBP-1 inhibits 
MMP-2 activation while also inducing miR-29b. miR-29b acts to repress 
Mcl-1, collagens, and pro–MMP-2 protein expression. Type I collagen 
normally promotes MMP-2 activation; thus, the combined repression 
of type I collagen and pro–MMP-2, plus MBP-1–dependent inhibition of 
MMP-2 activation, efficiently prevents its activation. Mcl-1 targeting by 
miR-29b meanwhile limits cellular survival and thus tumor growth.
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lysates were prepared 48 hours posttransfection. In addition, 
anti–miR-29b (Applied Biosystems) was transfected and 
cell lysates prepared for immunoblot analysis at 48 hours. 
Mcl-1 or MMP-2 expression was analyzed by Western blot 
using specific rabbit polyclonal antisera (Santa Cruz Bio-
technology, Santa Cruz, CA), followed by enhanced chemi-
luminescence (Amersham Biosciences, Piscataway, NJ) as 
described previously.10 Relative expression level was deter-
mined by densitometry, normalized to the expression of 
actin (mouse monoclonal; Santa Cruz Biotechnology).
Quantitative real-time RT-PCR. miRNA expression was 
determined by isolating total RNA using TRIzol reagent 
(Invitrogen, Carlsbad, CA). Total RNA (200 ng) was reverse 
transcribed using the TaqMan MicroRNA Reverse Tran-
scription kit (Applied Biosystems) with miRNA-specific 
primers. To quantify the miRNA levels, the 7500 Real-Time 
System (Applied Biosystems) was used in conjunction with 
gene-specific TaqMan assay kits (Applied Biosystems) for 
miR-29b and U6. U6 was used as an endogenous control to 
normalize expression. Relative miR-29b expression and 
standard error were calculated by the supplied 7500 Real-
Time System software.
Luciferase assay. Luciferase reporter constructs contain-
ing the putative miR-29b binding sites from Mcl-1,26 
Col1A1, Col3A1, and Col4A118,19 were as described previ-
ously. Constructs were co-transfected into PC-3 or DU145 
cells cultured in 12-well plates using Lipofectamine 2000. 
Briefly, 30 nM miRNA mimic or control miRNA was trans-
fected with 0.6 µg of the pMIR 3′UTR clones. Luciferase 
activity was measured 48 hours posttransfection using 
equal amount of protein as described previously.10
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